CENTRAL MACULAR THICKNESS AFTER COMBINED THERAPY OF BEVACIZUMAB INTRAVITREAL INJECTION AND TOPICAL DICLOFENAC COMPARED WITH BEVACIZUMAB INTRAVITREAL INJECTION IN DIABETIC MACULAR EDEMA

Melvina Nidya Sandra1, Yumni Shabrina1, Tri Wahyu Widayanti1, Retno Ekantini1, Agus Supartoto1, Muhammad Bayu Sasongko1, Supanji1

1 Department of Ophthalmology Universitas Gadjah Mada – Sardjito Hospital

Abstract

Introduction: To evaluate whether the combination of diclofenac eye drops and bevacizumab intravitreal injection would provide additional benefits over bevacizumab only in the treatment of naive diabetic macular edema (DME).

Methods: A total of 43 patients were randomized into two groups to receive combination treatment with bevacizumab intravitreal injection and topical diclofenac (group 1) or bevacizumab intravitreal injection only (group 2). Group 1 patients received single bevacizumab intravitreal injection and got self-administered diclofenac eye drop four times daily for one month. Group 2 patients received single bevacizumab intravitreal injection alone. Outcome data were achieved from patient visits at primary visit and at 1 month after bevacizumab intravitreal injection. All patients underwent measurement of best corrected visual acuity (BCVA), a complete eye examination, and measurement of central macular thickness (CMT).

Result: The mean reduction in CMT in the group 1 was 130.42±32.57 µm (p<0.01), while in the group 2 the reduction was 141.38±45.27 µm (p<0.01), there is no significant difference between the two groups (p=0.866). The mean improvement of BCVA was 0.32±0.10 log Mar in the combination group and 0.26±0.12 in group 2, there is no significant difference between the two groups (p=0.691). There was no adverse ocular event in the two groups.

Conclusion: In patients with naive DME, adding diclofenac eye drop as adjuvant of bevacizumab intravitreal injection are less likely to have a meaningful effect on reducing the central macular thickness.

Keywords: Diabetic macular edema, NSAID, diclofenac, anti-VEGF, bevacizumab, central macular thickness

INTRODUCTION

Diabetic macular edema (DME) can appear at various stages of diabetic retinopathy. DME has a prevalence of 6.8% of patients with diabetes mellitus. (1) DME is the most common cause of permanent visual loss in patients with diabetes. Intravitreal anti-VEGF has been widely used as therapy in DME but 30% of patients are resistant to this therapy (2) It can be thought that there are other mechanisms involved in the pathogenesis of DME, one of which is inflammation (3) Low-grade subclinical inflammation are responsible for the
development of DME. The expression of interleukin-6 (IL-6) and cyclooxygenase-2 are upregulated, therefore vascular permeability deteriorates.

Corticosteroids are an effective therapy because of their ability to fight inflammatory factors that contribute to DME but have many unwanted side effects such as cataracts and increased intraocular pressure. (4) In order to overcome this issue, alternative NSAIDs can be used as a strategy to get an anti-inflammatory effect without promoting side effects. Topical NSAIDs are widely used in the prevention and therapy in the case of cystoid macular edema after cataract extraction. (5) The use of topical NSAIDs combined with anti-VEGF has been shown to reduce retinal thickness in pseudophakic cystoid macular edema. (6) However, the effectiveness of the combination of topical NSAIDs and anti-VEGF in DME is not well known.

In this study, we prospectively evaluated whether the combination of diclofenac eye drops four times a day and intravitreal bevacizumab injections would provide additional benefits over bevacizumab only in patients with naïve DME.

METHODS

Data for this study were collected using a double-blind randomized controlled trial. The study included 43 patients with naïve DME. All patients were enrolled consecutively and randomized to receive combination treatment with bevacizumab intravitreal injection and topical diclofenac (group 1) or bevacizumab intravitreal injection (group 2). (7)

All patients received single bevacizumab intravitreal injection. Patients were self-administered with topical diclofenac four times a day for one month and the participants were evaluated.

Subjects were qualified if the following criteria were met: (1) patients diagnosed with DME by a retinal specialist; (2) age > 18 years; (3) never had corticosteroid/NSAIDs or prostaglandin analog therapy, anti-VEGF, and pan-retinal photocoagulation laser. Exclusion criteria were as follows: (1) patients with significant media opacity; (2) underwent intraocular surgery during the study period; (3) having anterior segment infection or inflammation.

The following assessments were performed by a blinded examiner at every visit: (1) measurement of BCVA; (2) assessment of adverse ocular event (e.g., infection, inflammation, endophthalmitis); (3) fully dilated opthalmic examination; (4) CMT measurement by OCT. Statistics were performed using the Wilcoxon test for changes in BCVA and CMT within the group. Between subgroups, Mann-Whitney analysis was used. Statistical analyses were performed using SPSS software.

RESULTS

A total of 43 patients met the study criteria and randomly assigned to either group 1 or group 2. One patient in group 1 drops out because the patient passed away. The table below illustrates the baseline characteristics of the participant group (group 1, bevacizumab and diclofenac; group 2, bevacizumab).

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n=22)</th>
<th>Group 2 (n=21)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, mean ± SD)</td>
<td>55.76±1.51</td>
<td>56.83±1.64</td>
<td>0.522</td>
</tr>
<tr>
<td>Sex (n,%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9 (38.1%)</td>
<td>5 (31.2%)</td>
<td>0.284</td>
</tr>
<tr>
<td>Female</td>
<td>13 (61.9%)</td>
<td>16 (68.7%)</td>
<td></td>
</tr>
<tr>
<td>CMT (μm)</td>
<td>466.90±45.81</td>
<td>437.50±37.11</td>
<td>0.355</td>
</tr>
<tr>
<td>BCVA (log Mar)</td>
<td>1.16±0.15</td>
<td>0.94±0.16</td>
<td>0.349</td>
</tr>
<tr>
<td>Intraocular pressure (mmHg)</td>
<td>16.19±0.98</td>
<td>16.61±1.01</td>
<td>0.791</td>
</tr>
</tbody>
</table>
As can be seen from the table below (table 2), the baseline means BCVA were 1.16±0.15 log Mar in group 1 and 0.94±0.16 log Mar in group 2. At 1 month follow up the mean BCVA group 1 were improved significantly to 0.83±0.12 (p=0.005) while in group 2 the improvement was not statistically significant (p=0.052). There was no statistically significant difference between the two treatment arms (p=0.691).

Table 2. BCVA and CMT between two groups.

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
<th>p (between group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCVA (log Mar)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>1.16±0.15</td>
<td>0.94±0.16</td>
<td></td>
</tr>
<tr>
<td>1 month</td>
<td>0.83±0.12</td>
<td>0.67±0.15</td>
<td></td>
</tr>
<tr>
<td>Difference</td>
<td>0.32±0.10</td>
<td>0.26±0.12</td>
<td>0.691</td>
</tr>
<tr>
<td>p (within group)</td>
<td>0.005</td>
<td>0.052</td>
<td></td>
</tr>
<tr>
<td>CMT (µm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>466.90±45.81</td>
<td>437.50±37.11</td>
<td></td>
</tr>
<tr>
<td>1 month</td>
<td>336.47±24.83</td>
<td>296.11±19.96</td>
<td></td>
</tr>
<tr>
<td>Difference</td>
<td>130.42±32.57</td>
<td>141.38±45.27</td>
<td>0.866</td>
</tr>
<tr>
<td>p (within group)</td>
<td>0.000</td>
<td>0.002</td>
<td></td>
</tr>
</tbody>
</table>

Group 1 = bevacizumab and diclofenac; Group 2 = bevacizumab.

From this data, it can be seen that CMT was significantly reduced in group 1 and group 2. In group 1 the mean reduction from baseline was 130.42±32.57 µm (p=0.000) while in group 2 was 141.38±45.27 µm (p=0.002). There was no statistically significant difference between the two treatment arms (p=0.866). There was no ocular adverse effect in both groups.

**DISCUSSION**

The result of this study suggests that there is likely no benefit in the addition of topical diclofenac in naïve DME. However, this outcome does not support the previous research where the combination of bevacizumab intravitreal injection and diclofenac intravitreal injection reduced CMT more than bevacizumab intravitreal injection only in patient with naïve diabetic macular edema. A possible explanation for this might be because the NSAIDs used were delivered directly to vitreous. Another study conducted by Warren showed greater retinal thickness reduction in patients who received combination of bevacizumab and intravitreal dexamethasone intravitreal injection with topical NSAID (nepafenac or bromfenac or ketorolac) compared to bevacizumab and dexamethasone intravitreal injection in patients with refractory diabetic macular edema. The bromfenac and nepafenac group required fewest number of additional intravitreal injection. The differences between this study and the study conducted by Warren are the naïve/refractory status of the diabetic macular edema and the NSAID used of this study were different. Compared with diclofenac, amfenac, and ketorolac, bromfenac is reported to be a 3 to 18 times more potent inhibitor of COX-2. COX-2 is thought to be primarily responsible for inflammation, and therefore the anti-inflammatory actions of NSAIDs are assumed to relate to their ability to inhibit this isoform. In a study comparing the efficacy of bromfenac, nepafenac, and diclofenac founded that bromfenac was more effective in preventing cystoid macular edema after cataract surgery than nepafenac. However, nepafenac is more effective in reducing inflammation than bromfenac. Nepafenac and bromfenac were more effective at reducing macular thickness in post-cataract macular edema compared to diclofenac.

A study conducted by Friedman et al founded that administration of topical nepafenac two times a day have no beneficial effect on retinal thickening and visual acuity outcome. This is contrary to reports showing a beneficial effect of nepafenac on macular edema in patients with diabetes. The difference might be caused by the different mechanism of macular edema, especially macular edema in the setting of cataract surgery. As with any study with topical eye drop treatment, patients’ compliance can affect the outcome.
VEGF is a potent vasopermeability factor that has been targeted extensively in DME. Compared with non-diabetic eyes, the VEGF levels are significantly increased in vitreous of DME patients.\textsuperscript{14} VEGF induced leukostasis in the retina, enhancing vascular permeability and capillary non-perfusion. Despite of being mostly a vasogenic factor, VEGF also trigger inflammation. VEGF induced ICAM-1 expression, leukocyte adhesion, and monocyte migration.\textsuperscript{15} The inflammatory process is also initiated by microglial cells, together with Muller cells and astrocytes, escalate this response and low-grade inflammation is preserved by the production of interleukin 6 (IL-6) and interleukin 8 (IL-8). IL-6 changes the function of astrocytes, thus breaking the inner blood-retinal barrier.\textsuperscript{16} Currently, the first line treatment in center-involving DME were anti-VEGF agents. However, despite the treatment, 40% of DME eyes endured persistent macular edema (PME) after 6 monthly injections, and 32% of DME eyes had concomitant visual loss based on the results from Protocol I and Protocol T.\textsuperscript{17, 18}

Several factors influence the prognosis of successful therapy in DME including the presence of wrinkled epiretinal membrane (ERM), presence of serous retinal detachment, disruption of external limiting membrane, hyper-reflective retinal spots, disruption of ellipsoid zone and the disorganization of inner retinal layers.

Increased CMT after treatment also considered predictor of poor response to treatment.\textsuperscript{19, 20} The limitation of this study were short follow up and the diagnostic criteria for macular edema were only based on the CMT despite the presence of hard exudate and macular ischemia, both of which could affect the results of this study.

CONCLUSIONS
The results of this study suggest that there is likely no benefit of adding diclofenac eye drop as an adjuvant of bevacizumab intravitreal injection in reducing CMT in patients with naïve DME. Further longer studies, which take presence of hard exudate and macular ischemia into account are necessary to establish whether or not adding diclofenac as an adjuvant may be of long-term benefit in the treatment of naïve DME.

REFERENCES


